chapter 17
DESCRIPTION
Chapter 17. Adrenergic Agonists. Adrenergic Agonists. Produce their effects by activating adrenergic receptors Sympathomimetic Broad spectrum of applications Congestive heart failure (CHF) Asthma Preterm labor. Mechanisms of Adrenergic Receptor Activation. Direct receptor binding - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/1.jpg)
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Chapter 17
Adrenergic Agonists
![Page 2: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/2.jpg)
2Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Adrenergic Agonists Produce their effects by activating adrenergic
receptors Sympathomimetic Broad spectrum of applications
Congestive heart failure (CHF) Asthma Preterm labor
![Page 3: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/3.jpg)
3Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Mechanisms of Adrenergic Receptor Activation
Direct receptor binding Promotion of norepinephrine (NE) release Inhibition of NE reuptake Inhibition of NE inactivation
![Page 4: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/4.jpg)
4Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Overview of Adrenergic Agonists Therapeutic applications and adverse effects
of adrenergic receptor activation Properties of representative adrenergic
agonists Discussion of adrenergic agonists in other
chapters
![Page 5: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/5.jpg)
5Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Overview of the Adrenergic Agonists
• Cannot be used orally (MAO and COMT)
• Brief duration of action• Cannot cross the blood-brain barrier
(polar molecules)
Catecholamines
• Can be given orally• Metabolized slowly by MAO—longer
half-life• More able to cross the blood-brain
barrier
Noncatecholamines
COMT = catechol-O-methyltransferase, MAO = monoamine oxidase.
![Page 6: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/6.jpg)
6Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Fig. 17–1. Structures of representative catecholamines and noncatecholamines.
![Page 7: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/7.jpg)
7Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Receptor specificity
• Most drugs in chapter • Peripherally acting
sympathomimetics• Direct receptor activation
• Amphetamine, cocaine• Indirect-acting
sympathomimetics
![Page 8: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/8.jpg)
8Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Receptor Specificity
• Beta2 onlyAlbuterol
• Beta1 and beta2Isoproterenol
• Alpha1 and alpha2 • Beta1 and beta2
Epinephrine
![Page 9: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/9.jpg)
9Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Therapeutic Applications and Adverse Effects of Adrenergic Receptor Activation
Clinical applications of alpha1 Two responses for therapeutic use
Vasoconstriction (most common use)• Blood vessels• Skin• Viscera• Mucous membranes
Mydriasis
![Page 10: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/10.jpg)
10Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Therapeutic Applications and Adverse Effects of Adrenergic Receptor Activation
Drugs capable of activating alpha1 receptors Epinephrine Norepinephrine Phenylephrine Dopamine
![Page 11: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/11.jpg)
11Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Therapeutic Applications and Adverse Effects of Adrenergic Receptor Activation
Therapeutic applications of alpha1 activation Hemostasis
• Arrests bleeding via vasoconstriction Nasal decongestion
• Mucosal vasoconstriction Adjunct to local anesthesia
• Delays absorption of local anesthetic Elevation of blood pressure
• Vasoconstriction Mydriasis
• Radial muscle of the iris
![Page 12: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/12.jpg)
12Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Therapeutic Applications and Adverse Effects of Adrenergic Receptor Activation
Adverse effects of alpha1 activation Hypertension
• Widespread vasoconstriction Necrosis
• Treatment with alpha1-blocking agent Bradycardia
• Response to vasoconstriction and elevated blood pressure (BP)
![Page 13: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/13.jpg)
13Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Clinical Consequences of Alpha2 Activation
Alpha2 receptors in periphery Located presynaptic ally Activation inhibits NE release
Alpha2 in CNS Reduction of sympathetic outflow to heart and
blood vessels Relief of severe pain
![Page 14: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/14.jpg)
14Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Clinical Consequences of Beta1 Activation
Therapeutic applications of beta1 activation Cardiac arrest
• Not preferred drug of choice Heart failure
• Positive inotropic effect Shock
• Positive inotropic effect; increases heart rate Atrioventricular heart block
• Enhances impulse conduction through atrioventricular (AV) node
![Page 15: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/15.jpg)
15Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Clinical Consequences of Beta1 Activation
Adverse effects of beta1 activation Altered heart rate or rhythm
• Tachycardias or dysrhythmias Angina pectoris
• Increased cardiac oxygen demand
![Page 16: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/16.jpg)
16Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Clinical Consequences of Beta2 Activation
Therapeutic applications of beta2 activation Asthma Delay of preterm labor
Adverse effects of beta2 activation Hyperglycemia Tremor
![Page 17: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/17.jpg)
17Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Clinical Consequences of Dopamine Receptor Activation
Activation of peripheral dopamine receptors causes dilation of the vasculature of the kidneys.
![Page 18: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/18.jpg)
18Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Multiple Receptor Activation: Treatment of Anaphylactic Shock
Pathophysiology of anaphylaxis Severe allergic response Hypotension, bronchoconstriction, edema of the
glottis Treatment
Epinephrine, injected IM, is the treatment of choice for anaphylactic shock.
![Page 19: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/19.jpg)
19Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Adrenergic Agonists Epinephrine Norepinephrine Isoproterenol Dopamine Dobutamine Phenylephrine Albuterol
![Page 20: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/20.jpg)
20Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Epinephrine Therapeutic uses
Delays absorption of local anesthetic Controls superficial bleeding Elevates blood pressure Mydriasis during ophthalmologic procedures Overcomes AV block Restores cardiac function in arrest Bronchial dilation in asthma Treatment of choice for anaphylactic shock
![Page 21: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/21.jpg)
21Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Epinephrine Pharmacokinetics
Absorption Inactivation
Adverse effects Hypertensive crisis Dysrhythmias Angina pectoris Necrosis following extravasation Hyperglycemia
![Page 22: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/22.jpg)
22Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Epinephrine Drug interactions
Monoamine oxidase (MAO) inhibitors Tricyclic antidepressants General anesthetics Alpha-adrenergic blocking agents Beta-adrenergic blocking agents
![Page 23: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/23.jpg)
23Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Epinephrine Preparations, dosage, and administration
EpiPen IV (monitor closely) IM SubQ Intracardiac—rarely used, only in asystole if IV not
available Intraspinal Inhalation Topical
![Page 24: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/24.jpg)
24Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Norepinephrine Receptor specificity
Alpha1
Alpha2
Beta1
Chemical classification Catecholamine
Therapeutic uses Hypotensive states Cardiac arrest
![Page 25: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/25.jpg)
25Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Norepinephrine Differs from epinephrine—does not activate
beta2 receptors Does not promote hyperglycemia
Cannot be given orally (MAO and COMT) Necrosis with extravasation Drug interactions
MAO inhibitors (MAOIs), tricyclic antidepressants (TCAs), general anesthetics, adrenergic blocking agents
![Page 26: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/26.jpg)
26Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Isoproterenol
Receptor specificity: beta1 and beta2 Chemical classification: catecholamine Therapeutic uses
Cardiovascular• AV heart block, arrest
Asthma• Bronchodilation—not used anymore
Bronchospasm• During anesthesia
![Page 27: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/27.jpg)
27Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Isoproterenol Adverse effects
Fewer than those of NE or epinephrine (does not activate alpha-adrenergic receptors)
Tachydysrhythmias and angina pectoris Hyperglycemia in diabetes patients
Drug interactions MAOIs, TCAs, beta-adrenergic blockers
Preparations and administration IV, IM, and intracardiac injections
![Page 28: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/28.jpg)
28Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Dopamine Receptor specificity
Low therapeutic dose: dopamine Moderate therapeutic dose: dopamine and beta1 Very high dose: apha1, beta1, and dopamine
![Page 29: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/29.jpg)
29Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Dopamine Therapeutic uses
Shock• Increases cardiac output• Increases renal perfusion
Heart failure• Increases myocardial contractility
Acute renal failure (ARF)• Was used to preserve renal function with ARF• Early ARF—failed to protect renal function, shorten
stays, or reduce need for renal transplant
![Page 30: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/30.jpg)
30Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Dopamine Adverse effects
Tachycardia, dysrhythmias, anginal pain Necrosis with extravasation
Drug interactions MAOIs, TCAs, certain general anesthetics,
diuretics Preparations, dosage, and administration
Preparations: dispensed in aqueous solutions Dosage: must be diluted Administration: administered by IV
![Page 31: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/31.jpg)
31Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Dobutamine
Receptor specificity: beta1 Chemical classification: catecholamine Actions and uses
CHF Adverse effects
Tachycardia Drug interactions
MAOIs, TCAs, certain general anesthetics Preparations, dosage, and administration
Continuous IV infusion
![Page 32: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/32.jpg)
32Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Phenylephrine Receptor specificity
Alpha1
Chemical classification Noncatecholamine
Therapeutic uses Reduces nasal congestion (locally) Elevates blood pressure (parenterally) Dilates pupils (eye drops) Local anesthetic (delays absorption)
![Page 33: Chapter 17](https://reader035.vdocuments.mx/reader035/viewer/2022062410/5681650b550346895dd77ff0/html5/thumbnails/33.jpg)
33Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc.
Albuterol
Receptor specificity: beta2 Chemical classification: noncatecholamine Therapeutic uses
Asthma (selective for beta2)• Replaced isoproterenol in treatment
Adverse effects Minimal at therapeutic doses Will activate beta1 receptors at higher doses Tremor most common; also tachycardia